Aiosyn
AI software for more accurate diagnostics in pathology and cancer care
Healthcare · Nijmegen · Founded 2021
- Founded
- 2021
- Total raised
- €4.4M
- Latest round
- Series A
- Location
- Nijmegen
What is being written
In the media
What they build
Overview
Aiosyn develops AI-powered software solutions for computational pathology, focusing on cancer and chronic kidney diseases. They integrate deep-learning algorithms into existing pathology workflows to enhance diagnostic accuracy, streamline operations, and accelerate drug development for clinical laboratories, research organizations, and biopharma companies. Their offerings include automated quality control for digital histology slides (AiosynQC), AI-assisted mitotic figure counting for breast cancer (Aiosyn Mitosis Breast), and precise quantification of kidney lesion scores via their NephroPath platform. Aiosyn aims to empower pathologists and support biopharma companies with data-driven insights to improve patient outcomes.
The people behind it
Team
Who believes in them
Investors & funding
Aiosyn raised €4.4M in total. The latest known round is Series A.
Where they are
Location
Nearby
Loading nearby…
Address
Nijmegen · GelderlandNo exact address
Frequently asked questions
Frequently asked questions
What does Aiosyn do?
AI software for more accurate diagnostics in pathology and cancer care
What sector is Aiosyn in?
Aiosyn operates in Healthcare.
Where is Aiosyn based?
Aiosyn is based in Nijmegen, Gelderland.
When was Aiosyn founded?
Aiosyn was founded in 2021.
Who founded Aiosyn?
Aiosyn was founded by Wouter Bulten, Jeroen van der Laak en Patrick de Boer.
How much funding has Aiosyn raised?
Aiosyn has raised €4.4M in funding in total.
Keep exploring